全文获取类型
收费全文 | 15803篇 |
免费 | 1921篇 |
国内免费 | 353篇 |
专业分类
耳鼻咽喉 | 89篇 |
儿科学 | 235篇 |
妇产科学 | 262篇 |
基础医学 | 694篇 |
口腔科学 | 166篇 |
临床医学 | 3301篇 |
内科学 | 1593篇 |
皮肤病学 | 260篇 |
神经病学 | 363篇 |
特种医学 | 465篇 |
外国民族医学 | 1篇 |
外科学 | 1263篇 |
综合类 | 1338篇 |
一般理论 | 4篇 |
预防医学 | 3227篇 |
眼科学 | 155篇 |
药学 | 3575篇 |
39篇 | |
中国医学 | 602篇 |
肿瘤学 | 445篇 |
出版年
2024年 | 52篇 |
2023年 | 506篇 |
2022年 | 578篇 |
2021年 | 1028篇 |
2020年 | 1049篇 |
2019年 | 974篇 |
2018年 | 945篇 |
2017年 | 952篇 |
2016年 | 895篇 |
2015年 | 854篇 |
2014年 | 1294篇 |
2013年 | 1807篇 |
2012年 | 1124篇 |
2011年 | 968篇 |
2010年 | 780篇 |
2009年 | 690篇 |
2008年 | 626篇 |
2007年 | 575篇 |
2006年 | 507篇 |
2005年 | 404篇 |
2004年 | 282篇 |
2003年 | 208篇 |
2002年 | 192篇 |
2001年 | 150篇 |
2000年 | 93篇 |
1999年 | 77篇 |
1998年 | 74篇 |
1997年 | 45篇 |
1996年 | 64篇 |
1995年 | 48篇 |
1994年 | 27篇 |
1993年 | 20篇 |
1992年 | 37篇 |
1991年 | 25篇 |
1990年 | 17篇 |
1989年 | 13篇 |
1988年 | 14篇 |
1987年 | 14篇 |
1986年 | 14篇 |
1985年 | 11篇 |
1984年 | 12篇 |
1983年 | 9篇 |
1982年 | 5篇 |
1981年 | 3篇 |
1980年 | 6篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1973年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
71.
基于RFID的病人用药安全管理新技术探讨 总被引:1,自引:0,他引:1
目前,我国在病人用药安全方面存在的主要问题是:病人本人用药安全意识淡漠、政府和卫生机构管理乏力、医院内部管理不规范、缺乏合适且有效的高新技术的支持。针对这些问题,提出基于先进的RFID技术的病人用药安全管理的新技术和解决方案,从而提高病患在用药过程中的安全系数,辅助相关医疗管理人员对药物进行准确有效的使用,防止用药安全事故的发生。 相似文献
72.
Dieter Ulrich Preiss Delawer Abdullah Bruno Eberspcher Karlheinz Wilhelm 《Thrombosis research》1992,65(6):677-686
In a prospective clinical trial the risk of infection after application of virus inactivated antithrombin III concentrate ANTITHROMBIN III IMMUNO (AT III) was investigated in patients undergoing cardiovascular surgery. The study was conducted according to the recommendations of the International Committee on Thrombosis and Hemostasis (ICTH), with the exception that most patients required additional blood products as well as AT III.
Twenty-seven patients were eligible to test for the risk of acquiring hepatitis B. Twenty-six patients could be evaluated in terms of hepatitis NANB transmission considering ALT-levels whereas 20 patients could be tested for anti-HCV one year after surgery. Samples from 78 patients could be monitored for anti-HIV-1. None of these patients showed any signs of infection. AT III IMMUNO seems to be an antithrombin III concentrate with low or absent infectivity. 相似文献
73.
Spartaco Bellomo 《Emerging infectious diseases》2005,11(6):985-987
74.
Ivermectin for the chemotherapy of bancroftian filariasis: a meta-analysis of the effect of single treatment 总被引:4,自引:4,他引:0
Wu-chun Cao Catharina P. B. Van der Ploeg Anton P. Plaisier I. J. Sivera van der Sluijs J. Dik F. Habbema 《Tropical medicine & international health : TM & IH》1997,2(4):393-403
Summary The efficacy and safety of ivermectin in the treatment of filariasis due to Wuchereria bancrofti was assessed by a meta-analysis of the results from 15 published clinical trials. Seven hundred and forty-eight microfilaraemic patients were enrolled in 7 dose-finding and 8 comparative studies. Administered as a single dose, ivermectin induced nearly complete clearance of microfilariae from the blood from the first day to 30 days post-treatment, followed by gradual recurrence of microfilaraemia and increase in its intensity. Higher doses of ivermectin showed greater clearance effects and maintained lower microfilaraemia levels for a longer time. The adverse reactions caused by the drug were flu-like, transient, generally mild and well tolerated by patients. The frequency and intensity of adverse reactions were strongly associated with pretreatment microfilaria counts in the blood, but independent of dose. The findings of the meta-analysis suggest that ivermectin given at a single annual dose of 200 μg/kg body weight or higher, whether or not in combination with DEC, has great potential for therapeutic strategies to control bancroftian filariasis. 相似文献
75.
76.
O. Z. Roy A. J. Mortimer B. J. Trollope E. J. Villeneuve 《Medical & biological engineering & computing》1984,22(3):225-228
Cardiac stimulation thresholds of short-duration large-amplitude electrical transients were studied. An isolated rabbit heart
model was used and transients were applied directly to the heart through electrodes of 1 mm2 and 1 cm2 surface area. A variety of oscillatory waveforms and pulse configurations were studied and indicated that, for transients
shorter than 100 μs, stimulation thresholds approach a constant charge-transfer density of 3·4 μC cm−2. 相似文献
77.
OBJECTIVE: To examine children's competence while cycling, as demonstrated in mistakes in performance and failure to comply with safety rules. METHODS: Children in three age groups (8, 10, and 12 years) participated in a realistic yet simulated traffic environment. RESULTS: The boys' cycling speed increased steadily with age, while that of the girls increased from 8 to 10 but decreased at age 12. Most children had adequate motor control by age 10, and the youngest compensated for their less developed skills by cycling slowly and braking early at junctions. Serious mistakes, often related to the children's age and gender, consisted of the children failing to stop at signals or stopping too late, especially at short stopping range. CONCLUSIONS: There are considerable individual differences in children's cycling competence that are related to biological factors, such as age and gender, and psychological factors, such as rule compliance and choice of cycling speed. 相似文献
78.
Fifty-eight patients with well-documented history of seasonal rhinoconjunctivitis caused by grass pollens were allocated randomly on a double-blind basis to receive either sublingual therapy with a solution of purified, standardized allergen preparation (Stallergenes) or a matched placebo for 17 weeks. The assessment of the effect of oral immunotherapy, done with drops of five-grass allergen extract, was on the clinical symptoms and on the medication score of the authorized rescue treatments. The actively treated patients had significantly (P<0.05 to P<0.01) fewer symptoms of rhinitis (sneezing and rhinorrhea) and of conjunctivitis (redness and tears) during the pollen season than the placebo group. Consumption of nasal solution of sodium cromoglycate and of betamethasone and dexchlorpheniramine was significantly less in the desensitized group (P<0.01). Side-effects were negligible. This study concludes that perlingual immunotherapy with grass pollen extract in grass-pollen-sensitive seasonal hay fever and conjunctivitis patients is effective, easy to perform, inexpensive, and safe. 相似文献
79.
Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis 总被引:1,自引:0,他引:1
C. Möller H. Ahlström† K.-Å. Henricson‡ L.-Å. Malmqvist§ A. Åkerlund¶ H. Hildebrand 《Clinical and experimental allergy》2003,33(6):816-822
BACKGROUND: Intranasal budesonide is an efficacious treatment for perennial allergic rhinitis. Long-term effects on safety, particularly in children, need further investigation. OBJECTIVE: To investigate the long-term safety of intranasal budesonide in children. METHODS: In an open trial, 78 children (5-15 years) with perennial rhinitis were treated with intranasal budesonide pressurized metered dose inhaler 200 microg twice daily (delivered daily dose 256 microg) for 12 months; 43 children stayed in the study for 12 additional months and were switched to aqueous suspension (400 microg delivered daily dose) for 6 months. Statural growth, bone age, ophthalmologic and rhinoscopic status, cortisol and biochemical analyses in blood and urine were monitored during the first and second years, and adverse events (AEs) were continuously recorded. RESULTS: No significant effects on statural growth and bone age, compared with reference values, were observed. Morning plasma cortisol and 24-h urinary cortisol were not changed during treatment. Patients reported 195 AEs, most commonly nasal dryness (30%), blood-tinged secretions (21%) and, among non-nasal AEs, headache (13%). Rhinoscopy revealed no signs of mucosal atrophy, ulceration, or candidiasis but some nasal dryness. No treatment-related ophthalmological or biochemical aberrations were found. Reduction of blood eosinophils and nasal symptom scores, compared with pre-treatment values, indicated the efficacy of budesonide treatment. CONCLUSION: Long-term treatment for 1-2 years with intranasal budesonide 256-400 microg daily in children with perennial rhinitis revealed no negative effects on growth or endogenous cortisol production. Local side-effects were mild and patient symptoms decreased. 相似文献
80.
Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma 总被引:3,自引:0,他引:3
Chapman KR Patel P D'Urzo AD Alexander M Mehra S Oedekoven C Engelstätter R Boulet LP 《Allergy》2005,60(3):330-337
BACKGROUND: Inhaled corticosteroids (ICS) are recommended therapy for persistent asthma, although side effects can limit appropriate use. Ciclesonide, a novel ICS, is activated in the lung, thereby reducing systemic activity and side effects. This 12-week, double-blind, randomized, parallel-group, placebo-controlled study evaluated the efficacy and safety of ciclesonide in adults with persistent asthma. METHODS: After a 2-week baseline period in which current ICS treatment was continued, 329 patients were randomized to receive ciclesonide 160 microg (n = 107) or 640 microg (n = 112) (ex-actuator doses, equivalent to 200 and 800 microg ex-valve, respectively), or placebo (n = 110) once daily in the morning. Efficacy was monitored by asthma symptom scores, rescue medication use, morning and evening peak expiratory flow (PEF) measurements, spirometry, and probability of study completion without experiencing lack of efficacy. RESULTS: Morning PEF remained stable with either ciclesonide dose but decreased with placebo; the differences were significant (P < 0.0001) for both ciclesonide doses vs placebo. The forced expiratory volume in 1 s and forced vital capacity decreased significantly with placebo (P < 0.005), but were unchanged with ciclesonide. Lack of efficacy was significantly greater for patients switched to placebo (63%) than it was for those treated with ciclesonide 160 microg (30%) (P < 0.0001 vs placebo) or ciclesonide 640 microg (31%) (P < 0.0001 vs placebo). There were no significant differences between the two tested doses of ciclesonide with respect to efficacy and safety. Serum and 24-h urine cortisol were unaffected by ciclesonide treatment. Both doses of ciclesonide were well tolerated with no cases of oral candidiasis. CONCLUSION: Ciclesonide (160 or 640 microg) once daily in the morning effectively maintains asthma control, does not affect cortisol levels, and has an adverse event profile comparable with placebo in adults with primarily mild to moderate asthma. 相似文献